Loading
A phase 2/3 trial of KRT-232 in endometrial cancer, run by Kartos Therapeutics, Inc., now recruiting.
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer is a phase 2/3 interventional study registered as NCT05797831 by Kartos Therapeutics, Inc., with 268 participants planned, started 2023-07-17 and due to reach its primary completion in 2025-08. Interventions recorded: Navtemadlin, Navtemadlin Placebo. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Kartos Therapeutics, KRT-232.
Shares Kartos Therapeutics, KRT-232.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/